Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
Open Access
- 24 September 2009
- journal article
- Published by American Society of Hematology in Blood
- Vol. 114 (13), 2733-2743
- https://doi.org/10.1182/blood-2009-03-213496
Abstract
The polycomb repressive complex (PRC) 2 contains 3 core proteins, EZH2, SUZ12, and EED, in which the SET (suppressor of variegation–enhancer of zeste-trithorax) domain of EZH2 mediates the histone methyltransferase activity. This induces trimethylation of lysine 27 on histone H3, regulates the expression of HOX genes, and promotes proliferation and aggressiveness of neoplastic cells. In this study, we demonstrate that treatment with the S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin A (DZNep) depletes EZH2 levels, and inhibits trimethylation of lysine 27 on histone H3 in the cultured human acute myeloid leukemia (AML) HL-60 and OCI-AML3 cells and in primary AML cells. DZNep treatment induced p16, p21, p27, and FBXO32 while depleting cyclin E and HOXA9 levels. Similar findings were observed after treatment with small interfering RNA to EZH2. In addition, DZNep treatment induced apoptosis in cultured and primary AML cells. Furthermore, compared with treatment with each agent alone, cotreatment with DZNep and the pan-histone deacetylase inhibitor panobinostat caused more depletion of EZH2, induced more apoptosis of AML, but not normal CD34+ bone marrow progenitor cells, and significantly improved survival of nonobese diabetic/severe combined immunodeficiency mice with HL-60 leukemia. These findings indicate that the combination of DZNep and panobinostat is effective and relatively selective epigenetic therapy against AML cells.Keywords
This publication has 50 references indexed in Scilit:
- Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cellsMolecular Cancer Therapeutics, 2006
- Polycomb silencers control cell fate, development and cancerNature Reviews Cancer, 2006
- EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsProceedings of the National Academy of Sciences, 2003
- The polycomb group protein EZH2 is involved in progression of prostate cancerNature, 2002
- Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphomaBlood, 2001
- The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphomaBritish Journal of Haematology, 2001
- Defining Roles for HOX and MEIS1 Genes in Induction of Acute Myeloid LeukemiaMolecular and Cellular Biology, 2001
- DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication fociNature Genetics, 2000
- Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-l-homocysteine hydrolase inhibitorAntiviral Research, 2000
- Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylationNature Genetics, 1999